Tag: Seattle Genetics

Finance

Biotech Insider Selling: Achillion Pharmaceuticals (NASDAQ:ACHN), Questcor Pharmaceuticals(NASDAQ:QCOR), Seattle Genetics (NASDAQ:SGEN), Repligen Corporation (NASDAQ:RGEN), bluebird bio (NASDAQ:BLUE)

Achillion Pharmaceuticals Inc (NASDAQ:ACHN) major shareholder Qvt Associates Gp Llc sold 128,649 shares of the company’s stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $7.66, for a total transaction of $985,451.34. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) stock performance was -6.32% in last session and finished the day at $6.38. Traded volume was 21.04million shares in the last … Continue reading Biotech Insider Selling: Achillion Pharmaceuticals (NASDAQ:ACHN), Questcor Pharmaceuticals(NASDAQ:QCOR), Seattle Genetics (NASDAQ:SGEN), Repligen Corporation (NASDAQ:RGEN), bluebird bio (NASDAQ:BLUE)

Mark DeFrance
Finance

NASDAQ Insider Buying: Bazaarvoice Inc (NASDAQ:BV), Seattle Genetics (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Career Education (NASDAQ:CECO), Acorn Energy (NASDAQ:ACFN)

Bazaarvoice Inc (NYSE:BV) President Eugene Austin purchased 10,000 shares of the company’s stock on the open market in a transaction dated Monday, June 9th. The stock was purchased at an average price of $7.05 per share, with a total value of $70,500.00. Following the acquisition, the president now directly owns 260,000 shares in the company, valued at approximately $1,833,000. Bazaarvoice Inc (NASDAQ:BV) stock performance was … Continue reading NASDAQ Insider Buying: Bazaarvoice Inc (NASDAQ:BV), Seattle Genetics (NASDAQ:SGEN), Corcept Therapeutics Incorporated (NASDAQ:CORT), Career Education (NASDAQ:CECO), Acorn Energy (NASDAQ:ACFN)

Kristen Barton
business, Finance

Mid Cap Insider Buying: Noble Corp. (NYSE:NE), WPX Energy (NYSE:WPX), DSW (NYSE:DSW), Opko Health (NYSE:OPK), Seattle Genetics (NASDAQ:SGEN)

Noble Co. (NYSE:NE) CEO David W. Williams bought 10,000 shares of the stock on the open market in a transaction that occurred on Friday, June 6th. The stock was purchased at an average price of $31.03 per share, with a total value of $310,300.00. Following the completion of the purchase, the chief executive officer now directly owns 390,282 shares of the company’s stock, valued at … Continue reading Mid Cap Insider Buying: Noble Corp. (NYSE:NE), WPX Energy (NYSE:WPX), DSW (NYSE:DSW), Opko Health (NYSE:OPK), Seattle Genetics (NASDAQ:SGEN)

Chris Lewis
Gilead Sciences GILD NASDAQ:GILD
Finance

Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance was -6.42% in last session and finished the day at … Continue reading Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

Kristen Barton
Finance

Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) on July 9 announced the pricing of its underwritten public offering of 2,017,349 shares of its common stock at a price to the public of $40.00 per share, before underwriting discounts. Ultragenyx is selling 1,311,277 shares of its common stock in this offering, and certain selling stockholders are selling 706,072 shares of common stock in this offering. Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) … Continue reading Biotech Stocks: Ultragenyx Pharmaceutical Inc (NASDAQ:RARE), Prosensa Holding NV (NASDAQ:RNA), Agios Pharmaceuticals Inc (NASDAQ:AGIO), Seattle Genetics, Inc. (NASDAQ:SGEN), Idera Pharmaceuticals Inc (NASDAQ:IDRA)

Adam Keintzel